Earlier chapters in this book have described the technologies used for gene transfer and the manufacturing and regulatory requirements required to safely and legally exploit these technologies. This final chapter describes some of the obstacles to developing gene therapies from these early-phase clinical studies so that they can become licensed agents that are standards of practice as cancer therapeutics. Also outline are some of the remaining scientific limitations that will need to be addressed if gene therapies are to reach their broadest potential.
- Cell therapy for cancer
- Clinical trial design for biologicals
- Drug development using biologicals
- Gene therapy for cancer
ASJC Scopus subject areas